News Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 23:00:00 23/06/2026 +03			5-day change	1st Jan Change
20.71 ^USD	+10.93%		+14.29%	+32.08%

05-07	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q1 Revenue $4.2M, vs. FactSet Est of $11.4M	MT

All News

Mentions Relevance

06-02	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
05-20	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	AQ
05-07	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Monte Rosa Therapeutics: Q1 Earnings Snapshot	AQ
05-07	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q1 Revenue $4.2M, vs. FactSet Est of $11.4M	MT
05-07	Monte Rosa Therapeutics : Corporate Presentation – May 2026	PU
05-07	Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates	AQ
05-05	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
04-22	Monte Rosa Therapeutics : AACR 2026 – Selective targeting of CCNE1 using molecular glue degraders for the treatment of CCNE1 amplified cancers	PU
04-20	Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors	GL
04-20	Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2026 on the Potential of its Cyclin E1-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors	CI
03-17	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-17	Monte Rosa Therapeutics, Inc. Announces Executive Changes	CI
03-17	Monte Rosa Therapeutics Swings to Net Loss in Q4, Collaboration Revenue Falls	MT
03-17	Monte Rosa Therapeutics: Q4 Earnings Snapshot	AQ
03-17	Monte Rosa Therapeutics : Corporate Presentation – March 2026	PU
03-17	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q4 Revenue $2.8M	MT
03-17	Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates	AQ
03-16	Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer	CI
03-16	Monte Rosa Therapeutics announces clinical supply agreement to support phase 2 trial evaluating MRT-2359 in combination with apalutamide for the treatment of metastatic castration-resistant prostate cancer	RE
03-16	Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer	AQ
03-03	Monte Rosa Therapeutics Insider Sold Shares Worth $464,886, According to a Recent SEC Filing	MT
02-26	Monte Rosa Therapeutics : Corporate Presentation – February 2026	PU
02-26	Monte Rosa Therapeutics : ASCO Genitourinary Cancers Symposium 2026 – MRT-2359 in Combination with Enzalutamide Suppresses Multiple Oncogenic Pathways to Drive Deep and Durable PSA and RECIST Responses in Heavily Pretreated, Metastatic Castration-Resistant Prostate Cancer Harbori	PU
02-24	Monte Rosa Therapeutics, Inc. Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients At Asco Genitourinary Cancers	CI